NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $0.76 +0.00 (+0.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.09%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nautilus Biotechnology Stock (NASDAQ:NAUT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nautilus Biotechnology alerts:Sign Up Key Stats Today's Range$0.74▼$0.7950-Day Range$0.69▼$0.8252-Week Range$0.66▼$3.09Volume139,938 shsAverage Volume156,050 shsMarket Capitalization$96.42 millionP/E RatioN/ADividend YieldN/APrice Target$2.13Consensus RatingSell Company Overview Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Read More Nautilus Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNAUT MarketRank™: Nautilus Biotechnology scored higher than 66% of companies evaluated by MarketBeat, and ranked 310th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingSell Consensus RatingNautilus Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNautilus Biotechnology has received no research coverage in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nautilus Biotechnology has recently decreased by 18.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.41% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nautilus Biotechnology has recently decreased by 18.92%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.15 News SentimentNautilus Biotechnology has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.Search Interest1 people have searched for NAUT on MarketBeat in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,405.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Stock News HeadlinesNautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call TranscriptAugust 1 at 5:04 PM | seekingalpha.comNautilus Biotechnology Reports Second Quarter 2025 Financial ResultsJuly 31 at 8:00 AM | globenewswire.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 2 at 2:00 AM | Banyan Hill Publishing (Ad)Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule ProteomicsJuly 31 at 2:31 AM | tmcnet.comNautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025July 15, 2025 | finance.yahoo.comNautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025July 15, 2025 | globenewswire.comNautilus Biotechnology Inc Ordinary Shares - MorningstarJuly 2, 2025 | morningstar.comMInsiders of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) have had a great week after last week's US$12m gain and they haven't stopped buyingJune 27, 2025 | finance.yahoo.comSee More Headlines NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $1.68 at the beginning of 2025. Since then, NAUT stock has decreased by 54.5% and is now trading at $0.7643. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Thursday, July, 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Read the conference call transcript. Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's top institutional investors include Clarius Group LLC (0.84%), Y Intercept Hong Kong Ltd (0.18%), Callan Family Office LLC (0.04%) and Presidio Capital Management LLC (0.03%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld and Mary E Godwin. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nautilus Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V). Company Calendar Last Earnings7/31/2025Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:NAUT CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Price Target for Nautilus Biotechnology$2.13 High Price Target$2.50 Low Price Target$1.75 Potential Upside/Downside+178.0%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.45% Return on Assets-26.99% Debt Debt-to-Equity RatioN/A Current Ratio17.36 Quick Ratio17.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book0.46Miscellaneous Outstanding Shares126,150,000Free Float74,301,000Market Cap$96.42 million OptionableOptionable Beta1.42 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NAUT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.